Evotec Enters License Agreement with Broad Institute
News Jul 07, 2016
Evotec AG has announced that it has entered into a non-exclusive licence agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology.
Under the terms of this research tool licence, Evotec gains access to IP related to CRISPR-Cas9 and will apply the technology to its drug discovery offerings and R&D activities, especially for the development of research tools and in target identification, and to further strengthen its post phenotypical screening target deconvolution platform.
With this agreement, Evotec obtains non-exclusive access to the leading technology on the market for gene editing.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "Alongside Evotec's comprehensive stem cell capabilities, the ability to offer CRISPR-Cas9 research tools emphasises the Company's continuing approach to establishing cutting-edge technologies for the benefit of our partners and growing R&D pipeline."
In a new study in cells, University of Illinois researchers have adapted CRISPR gene-editing technology to cause the cell’s internal machinery to skip over a small portion of a gene when transcribing it into a template for protein building. This gives researchers a way not only to eliminate a mutated gene sequence, but to influence how the gene is expressed and regulated.